Loomis Sayles & Co. L P Has $4.25 Million Position in InMode Ltd. (NASDAQ:INMD)

Loomis Sayles & Co. L P trimmed its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 254,420 shares of the healthcare company’s stock after selling 27,644 shares during the period. Loomis Sayles & Co. L P owned about 0.37% of InMode worth $4,249,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of INMD. River Road Asset Management LLC acquired a new stake in shares of InMode during the 4th quarter worth about $8,572,000. Seizert Capital Partners LLC lifted its position in InMode by 105.2% during the fourth quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company’s stock worth $4,185,000 after acquiring an additional 128,483 shares during the last quarter. Systematic Financial Management LP boosted its holdings in shares of InMode by 13.3% during the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after acquiring an additional 115,492 shares during the period. Barclays PLC grew its position in shares of InMode by 113.5% in the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after purchasing an additional 90,173 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its position in shares of InMode by 12.9% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company’s stock valued at $12,217,000 after purchasing an additional 82,100 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on INMD shares. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Barclays boosted their target price on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.25.

InMode Trading Down 3.3 %

Shares of InMode stock opened at $17.70 on Friday. The company has a market cap of $1.23 billion, a PE ratio of 7.53 and a beta of 2.08. The company has a 50 day moving average of $18.32 and a 200-day moving average of $17.78. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $21.76.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.